07:55 AM EDT, 07/23/2025 (MT Newswires) -- Waldencast ( WALD ) said Wednesday that it has agreed to acquire dermatological firm Novaestiq, as well as the US rights to the Saypha line of hyaluronic acid injectable gels, in a cash-and-stock deal.

Waldencast ( WALD ) said it has agreed to acquire Novaestiq in exchange for a combination of upfront cash, perpetual royalties based on sales, and the contingent issuance of 7% of Waldencast's ( WALD ) class A shares upon the achievement of certain milestones, such as the receipt of US FDA approval and sales of Saypha fillers.

Waldencast ( WALD ) said the acquisition will expand the footprint of its unit Obagi Medical into the US dermal filler market.